Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,525 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26878
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–25 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

BTK inhibitors are associated with a lower risk of myeloid neoplasms and non-melanoma skin cancer compared with chemoimmunotherapy in chronic lymphocytic leukemia: a propensity score-matched analysis.
Pratik Shah, Adit Singhal, Yu-Cheng Chang et al. · Leukemia · Aug 10, 2026 · PMID 42575952 · candidate dictionary pubmed
EGFR T790M resistance mutation in non small-cell lung carcinoma.
· Clin Chim Acta · 2015 · PMID 25668228 · validated civic_curation pubmed
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
· N Engl J Med · 2010 · PMID 20979469 · validated civic_curation pubmed
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
· N Engl J Med · 2013 · PMID 23724913 · validated civic_curation pubmed
First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
· N Engl J Med · 2014 · PMID 25470694 · validated civic_curation pubmed
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
· Lancet Oncol · 2016 · PMID 26708155 · validated civic_curation pubmed
Osimertinib: First Global Approval.
· Drugs · 2016 · PMID 26729184 · validated civic_curation pubmed

Showing 1–25 of 916 publications

← Previous
1
2
…
37
Next →

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

· N Engl J Med · 2017 · PMID 27959700 · validated civic_curation pubmed

U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.

· Oncologist · 2014 · PMID 24868098 · validated civic_curation pubmed

Afatinib: first global approval.

· Drugs · 2013 · PMID 23982599 · validated civic_curation pubmed

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SELECT-1 Randomized Clinical Trial.

· JAMA · 2017 · PMID 28492898 · validated civic_curation pubmed

Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001.

· Ann Oncol · 2019 · PMID 30980071 · validated civic_curation pubmed

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

· N Engl J Med · 2017 · PMID 28586279 · validated civic_curation pubmed

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28602779 · validated civic_curation pubmed

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

· N Engl J Med · 2019 · PMID 31157963 · validated civic_curation pubmed

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.

· Lancet · 2017 · PMID 28501140 · validated civic_curation pubmed

Olaparib for Metastatic Castration-Resistant Prostate Cancer.

· N Engl J Med · 2020 · PMID 32343890 · validated civic_curation pubmed

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

· N Engl J Med · 2021 · PMID 34096690 · validated civic_curation pubmed

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

· Lancet Oncol · 2020 · PMID 32416072 · validated civic_curation pubmed

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial.

· J Clin Oncol · 2020 · PMID 32780660 · validated civic_curation pubmed

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

· Lancet Oncol · 2020 · PMID 31838015 · validated civic_curation pubmed

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

· N Engl J Med · 2021 · PMID 34081848 · validated civic_curation pubmed

Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.

· N Engl J Med · 2020 · PMID 32955177 · validated civic_curation pubmed

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

· Lancet Oncol · 2017 · PMID 28958502 · validated civic_curation pubmed

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

· Lancet Oncol · 2019 · PMID 31591063 · validated civic_curation pubmed